Please try another search
Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical trials for the treatment of solid tumors. The company was founded in 2017 and is based in Shanghai, China.
Name | Age | Since | Title |
---|---|---|---|
Wang Xuegong | 51 | 2020 | Independent Director |
Zhang Xin | 51 | 2020 | Independent Director |
Lu Simon | 55 | 2017 | Director |
Guanshan Zhu | 59 | 2020 | Independent Director |
Dong Weiwen | 37 | - | Chairman of the Supervisory Board |
Rodolphe Grepinet | 50 | 2017 | Director |
Jiang Bin | 59 | 2020 | Independent Director |
Yuan Sun | 36 | - | Supervisor |
Xiaojing Kang | 48 | 2022 | Employee Supervisor |
Zhang Xiaolin | 60 | - | GM & Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review